ArticleVirchows Archiv : an international journal of pathology2026
ERBB2/ERBB3‑mutated S100/SOX10‑positive high‑grade uterine sarcoma-a case report on a rare entity.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
ERBB2/ERBB3‑mutated S100/SOX10‑positive uterine sarcoma is a recently described entity with distinct morphological, immunophenotypic, and molecular features, representing a subset of high-grade uterine sarcomas. This tumor is characterized by ERBB2/ERBB3 mutations or ERBB2 amplification, which leads to the overexpression or constitutive activation of HER2. The presence of HER2 amplification represents a potential target for the treatment with HER2 inhibitors. Here we present a case of high-grade uterine cervix sarcoma with ERBB2 amplification and S100/SOX10 expression in a 58-year-old patient. The tumor measured 50 mm at its largest dimension and recurred two years after surgery. Histologically, the tumor was composed of round and spindle cell, showing diffuse nuclear expression of SOX10 and both nuclear and cytoplasm expression of S100. It also demonstrated ERBB2 amplification, as well as mutations in ATRX and BACH1. Accurate recognition of such tumors is crucial due to their propensity for aggressive behavior and the availability of potential targeted therapeutic options.
Indexed as
Identifiers
41026178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.